Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843936 | 0.87 | CYP2C19 (0.35) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL1844674 | 0.81 | ADRB2 (0.40) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL27635623 | 0.78 | CYP2C19 (0.38) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL1841133 | 0.78 | CYP2C19 (0.38) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL27377535 | 0.78 | SMN1; SMN2 (0.42) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL16268203 | 0.77 | HTR7 (0.45) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL2311217 | 0.76 | CYP2C19 (0.46) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| Hydrochloric Acid SCHEMBL4346321 | 0.76 | SMN1; SMN2 (0.41) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL3281612 | 0.76 | CYP2C19 (0.39) | CYP2C19KDM1AMAOBTRPM5FDPS | |
| SCHEMBL25169914 | 0.74 | CYP2C19 (0.40) | CYP2C19KDM1AMAOBTRPM5FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529053-B1 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON SPA (IT) | 2011-05-18 | — | — | EP | claimed |
| US-7488811-B2 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2009-02-10 | — | — | US | claimed |
| US-20060058246-A1 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2006-03-16 | — | — | US | claimed |
| EP-1529053-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2005-05-11 | — | — | EP | claimed |
| WO-2004013153-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2004-02-12 | — | — | WO | claimed |
| EP-2258708-A1 | Macrolide compounds endowed with antiinflammatory activity | Zambon S.p.A. (IT) | 2010-12-08 | — | — | EP | disclosed |
| US-7704960-B2 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| US-20090054357-A1 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2009-02-26 | — | — | US | disclosed |
| US-7488811-B2 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2009-02-10 | — | — | US | disclosed |
| US-20060058246-A1 | Macrolide compounds endowed with antiinflammatory activity | ZAMBON GROUP S.P.A. (IT) | 2006-03-16 | — | — | US | disclosed |
| EP-1529053-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.p.A. (IT) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004013153-A2 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | ZAMBON GROUP S.P.A. (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054357-A1 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY | CEL, MPO, IL6 | CYP2C19 1558/4885KDM1A 4267/4885MAOB 3239/4885 |
| US-20060058246-A1 | Macrolide compounds endowed with antiinflammatory activity | CEL, MPO, IL6 | CYP2C19 1558/4885KDM1A 4267/4885MAOB 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.